Literature DB >> 27245758

Is (18)FDG uptake useful to decide on chemotherapy in ER+/HER2- breast cancer?

David Groheux1,2, Elif Hindié3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27245758     DOI： 10.1007/s00259-016-3430-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  17 in total

1.  Additional value of PET-CT in staging of clinical stage IIB and III breast cancer.

Authors:  Isabelle Segaert; Felix Mottaghy; Sarah Ceyssens; Walter De Wever; Sigrid Stroobants; Chantal Van Ongeval; Eric Van Limbergen; Hans Wildiers; Robert Paridaens; Ignace Vergote; Marie-Rose Christiaens; Patrick Neven
Journal:  Breast J       Date:  2010 Nov-Dec       Impact factor: 2.431

2.  Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.

Authors:  David Groheux; Sylvie Giacchetti; Jean-Luc Moretti; Raphael Porcher; Marc Espié; Jacqueline Lehmann-Che; Anne de Roquancourt; Anne-Sophie Hamy; Caroline Cuvier; Laetitia Vercellino; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-06       Impact factor: 9.236

3.  Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?

Authors:  David Groheux; Mohamed Majdoub; Florent Tixier; Catherine Cheze Le Rest; Antoine Martineau; Pascal Merlet; Marc Espié; Anne de Roquancourt; Elif Hindié; Mathieu Hatt; Dimitris Visvikis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-04       Impact factor: 9.236

Review 4.  Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Lyndsay N Harris; Nofisat Ismaila; Lisa M McShane; Fabrice Andre; Deborah E Collyar; Ana M Gonzalez-Angulo; Elizabeth H Hammond; Nicole M Kuderer; Minetta C Liu; Robert G Mennel; Catherine Van Poznak; Robert C Bast; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2016-02-08       Impact factor: 44.544

Review 5.  Performance of FDG PET/CT in the clinical management of breast cancer.

Authors:  David Groheux; Marc Espié; Sylvie Giacchetti; Elif Hindié
Journal:  Radiology       Date:  2012-12-06       Impact factor: 11.105

6.  Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.

Authors:  Su Hyun Lee; Seunggyun Ha; Hyun Joon An; Jae Sung Lee; Wonshik Han; Seock-Ah Im; Han Suk Ryu; Won Hwa Kim; Jung Min Chang; Nariya Cho; Woo Kyung Moon; Gi Jeong Cheon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-05-21       Impact factor: 9.236

7.  Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.

Authors:  David Groheux; Mathieu Hatt; Elif Hindié; Sylvie Giacchetti; Patricia de Cremoux; Jacqueline Lehmann-Che; Antoine Martineau; Michel Marty; Caroline Cuvier; Catherine Cheze-Le Rest; Anne de Roquancourt; Dimitris Visvikis; Marc Espié
Journal:  Cancer       Date:  2013-03-15       Impact factor: 6.860

Review 8.  ¹⁸F-FDG PET/CT for Staging and Restaging of Breast Cancer.

Authors:  David Groheux; Alexandre Cochet; Olivier Humbert; Jean-Louis Alberini; Elif Hindié; David Mankoff
Journal:  J Nucl Med       Date:  2016-02       Impact factor: 10.057

9.  Utility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer.

Authors:  Kenjiro Aogi; Takayuki Kadoya; Yoshifumi Sugawara; Sachiko Kiyoto; Hideo Shigematsu; Norio Masumoto; Morihito Okada
Journal:  Breast Cancer Res Treat       Date:  2015-02-20       Impact factor: 4.872

10.  [18F]-fluorodeoxyglucose positron emission tomography can contribute to discriminate patients with poor prognosis in hormone receptor-positive breast cancer.

Authors:  Sung Gwe Ahn; Minkyung Lee; Tae Joo Jeon; Kyunghwa Han; Hak Min Lee; Seung Ah Lee; Young Hoon Ryu; Eun Ju Son; Joon Jeong
Journal:  PLoS One       Date:  2014-08-28       Impact factor: 3.240
View more
  1 in total

1.  Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients.

Authors:  Charles Lemarignier; Antoine Martineau; Luis Teixeira; Laetitia Vercellino; Marc Espié; Pascal Merlet; David Groheux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-10       Impact factor: 9.236
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.